Axitinib

Drug Profile

Axitinib

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Tumores Neuroendocrinos; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; SCRI Development Innovations; SFJ Pharmaceuticals; University of Cincinnati; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Eye disorder therapies; Imidazoles; Indazoles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II/III Neuroendocrine tumours
  • Phase II Carcinoid tumour; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Prostate cancer
  • Phase I Hepatocellular carcinoma
  • No development reported Solid tumours
  • Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy, Late-stage disease, Treatment-naive) in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Poland (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Spain (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top